Literature DB >> 19073834

CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.

Andreas Fellgiebel1, Elzbieta Kojro, Matthias J Müller, Armin Scheurich, Lutz G Schmidt, Falk Fahrenholz.   

Abstract

We exploratively measured APPs alpha, a secreted fragment of the non-amyloidogenic cleavage of amyloid precursor protein via a-secretase, and tau protein phosphorylated at threonine 181 (p tau) in the cerebrospinal fluid of 10 patients with mild cognitive impairment, 20 patients with dementia of Alzheimer's type, and 10 controls. Cerebrospinal fluid APPs alpha and p tau levels were correlated with cognitive performance. P tau levels were significantly elevated in mild cognitive impairment and in patients with dementia of Alzheimer's type, APPs alpha levels were significantly reduced in patients with dementia of Alzheimer's type compared to the controls. APPs alpha levels were associated with Mini Mental State Examination total scores but not with Delayed Verbal Recall Test performance. Vice versa, pt au levels correlated only with Delayed Verbal Recall Test in patients with dementia of Alzheimer's type or mild cognitive impairment. Both, an increase in p tau levels and a decrease in cerebrospinal fluid APPs alpha, seem to refer to relevant but functionally different processes in the development of mild cognitive impairment and dementia of Alzheimer's type.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073834     DOI: 10.1177/0891988708327810

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  12 in total

Review 1.  Regulation of α-secretase ADAM10 expression and activity.

Authors:  Kristina Endres; Falk Fahrenholz
Journal:  Exp Brain Res       Date:  2011-10-04       Impact factor: 1.972

2.  ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons.

Authors:  Peer-Hendrik Kuhn; Huanhuan Wang; Bastian Dislich; Alessio Colombo; Ulrike Zeitschel; Joachim W Ellwart; Elisabeth Kremmer; Steffen Rossner; Stefan F Lichtenthaler
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

3.  The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein.

Authors:  Sylvia Ullrich; Anna Münch; Stephanie Neumann; Elisabeth Kremmer; Jörg Tatzelt; Stefan F Lichtenthaler
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

4.  Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.

Authors:  Sven Lammich; Dominik Buell; Sonja Zilow; Ann-Katrin Ludwig; Brigitte Nuscher; Stefan F Lichtenthaler; Claudia Prinzen; Falk Fahrenholz; Christian Haass
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

5.  MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10).

Authors:  Cong Cheng; Weiguang Li; Zheng Zhang; Shohei Yoshimura; Qinyu Hao; Chi Zhang; Zhao Wang
Journal:  J Biol Chem       Date:  2013-04-01       Impact factor: 5.157

6.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

7.  CSF phospho-tau is independent of age, cognitive status and gender of neurological patients.

Authors:  Armin Scheurich; Peter P Urban; Nassrin Koch-Khoury; Andreas Fellgiebel
Journal:  J Neurol       Date:  2009-11-17       Impact factor: 4.849

8.  BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.

Authors:  Anna L Stern; Shivesh Ghura; Patrick J Gannon; Cagla Akay-Espinoza; Jessica M Phan; Alan C Yee; Robert Vassar; Benjamin B Gelman; Dennis L Kolson; Kelly L Jordan-Sciutto
Journal:  J Neurosci       Date:  2018-04-09       Impact factor: 6.167

Review 9.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

10.  Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice.

Authors:  Dorothea Rat; Ulrich Schmitt; Frank Tippmann; Ilse Dewachter; Clara Theunis; Ewa Wieczerzak; Rolf Postina; Fred van Leuven; Falk Fahrenholz; Elzbieta Kojro
Journal:  FASEB J       Date:  2011-05-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.